Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
In a recent Phase 2 study presented in June 2025, combining it with semaglutide (the active ingredient in Wegovy) led to remarkable outcomes for participants with obesity: An average weight loss of 22% over 72 weeks (compared to 16% with semaglutide alone) About 93% of that loss coming from fat mass, with minimal impact on lean muscle A 58% drop in visceral fat (versus 36% with semaglutide alone) All achieved without requiring dietary or exercise modifications This stands out because typical weight-loss drugs, like GLP-1 agonists, often result in losing both fat and musclea downside, since muscle boosts metabolism and supports overall health as we age
This can be particularly detrimental when using semaglutide, as it is designed to help regulate your appetite and blood sugar levels
Seek immediate medical attention if you experience chest pain, difficulty swallowing, persistent vomiting, or signs of gastrointestinal bleeding alongside reflux
Failure to Warn Allegations Lawsuits against Novo Nordisk and Eli Lilly are built on allegations that both pharmaceutical companies failed to properly warn consumers about the health risks tied to their GLP-1 drugs
Where the evidence has been randomised and the endpoints uncontested, review teams have been closing files ahead of the PDUFA framework rather than against it
"Management of gastroparesis-associated malnutrition"
US$ 23.86
US$ 25.73
US$ 21.38
US$ 23.56
US$ 29.94
US$ 21.61
US$ 29.63
